Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report

Background Posterior Reversible Encephalopathy Syndrome (PRES) is a neurotoxic state characterized by seizures, headache, vision change, paresis, and altered mental status. PRES has an important place in medicine due to the wide variety of causative diseases, infections, and medications that precipi...

Full description

Saved in:
Bibliographic Details
Published in:BMC neurology 2022-08, Vol.22 (1), p.1-318, Article 318
Main Authors: Puram, Vikram V, Ghazaleh, Dana, Salari, Apameh, McCleary, Kaci, Moriarty, Gerald, Nichols, Kendall, Ghannam, Malik, Brown, Kevin, Berry, Brent
Format: Article
Language:English
Subjects:
Asthma
Blood pressure
Cancer
Care and treatment
Case Report
Chemotherapy
Churg-Strauss syndrome
Development and progression
Diagnosis
Dosage and administration
Drug dosages
Drug reaction
Edema
Encephalitis
Encephalopathy
Granulomatosis
Headaches
Hospitalization
Hospitals
Hypertension
Immunosuppressive agents
Leukocytes (eosinophilic)
Medical imaging
Mepolizumab
Neuroimaging
Neurotoxicity
Paresis
Patient outcomes
Patients
Posterior reversible encephalopathy syndrome
Seizures
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Posterior Reversible Encephalopathy Syndrome (PRES) is a neurotoxic state characterized by seizures, headache, vision change, paresis, and altered mental status. PRES has an important place in medicine due to the wide variety of causative diseases, infections, and medications that precipitate its mysterious onset. Although exposure to medications, particularly immunosuppressants, cancer chemotherapy, and biologic drugs, is a common occurrence in patients who develop PRES, Mepolizumab has never before been associated. Case presentation This report of a 67-year-old male patient outlines the first reported case of Mepolizumab-induced PRES in the literature. Conclusions Treatment of severe asthma, asthma-exacerbations, and diseases such as eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) with Mepolizumab is rapidly gaining popularity ever since the drug's recent FDA-approval. This report aims to raise awareness of this potentially life-threatening and previously unreported side effect of Mepolizumab since early identification of the causative agent is the key to preventing the severe neurologic disability and possible death that may occur from the delayed treatment of PRES. Keywords: Mepolizumab, Posterior reversible encephalopathy syndrome, Asthma, Drug reaction
ISSN:1471-2377
1471-2377
DOI:10.1186/s12883-022-02849-1